BridgeBio Pharma (BBIO) Total Liabilities (2017 - 2026)

BridgeBio Pharma has disclosed Total Liabilities across 10 years of filings, most recently posting $3.6 billion for Q1 2026.

• Total Liabilities for Q1 2026 came in at $3.6 billion, up 44.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 billion (up 44.42% YoY), and the FY2025 annual result was $3.0 billion, up 26.74% from the prior year.
• Total Liabilities came in at $3.6 billion for Q1 2026 at BridgeBio Pharma, up from $3.0 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $3.6 billion in Q1 2026 to a low of $1.8 billion in Q1 2023.
• The 5-year median for Total Liabilities is $1.9 billion (2024), against an average of $2.2 billion.
• Across the five-year window, Total Liabilities retreated 1.28% in 2023 and surged 55.09% in 2025, its largest moves.
• BridgeBio Pharma's Total Liabilities stood at $1.9 billion in 2022, then climbed by 1.12% to $1.9 billion in 2023, then advanced by 25.84% to $2.4 billion in 2024, then gained by 26.74% to $3.0 billion in 2025, then rose by 20.82% to $3.6 billion in 2026.
• The last three Total Liabilities figures came in at $3.6 billion (Q1 2026), $3.0 billion (Q4 2025), and $2.9 billion (Q3 2025), per Business Quant data.